cnbc.com / .cnbc-com-health-care / Page 3

Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma consolidation.

Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.

CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.

Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.

Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.

Chipotle has pulled the affected supply from restaurants and replaced them with peppers from different growers, according to the company.

P&G CEO Shailesh Jejurikar said the acquisition is play to grow the company's health business on CNBC's "Squawk on the Street."

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.

Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.